Director William Hoffman Cashes Out 25000 Shares of Inari Medical
November 22, 2023
☀️Trending News
Inari Medical ($NASDAQ:NARI) Inc. has recently announced that William Hoffman, a Director of the company, has sold 25,000 of its shares. Inari Medical is a publicly traded medical device company dedicated to transforming patient care through innovative interventional products. The company focuses on developing minimally invasive treatments for peripheral vascular diseases, including stroke, embolization, and clot management. Inari Medical’s products are used in a wide range of medical procedures in hospitals and other medical settings worldwide. The stock price has dropped following the news, leading some to speculate that the company may be headed for a decline.
However, analysts have noted that it is too early to make any definitive conclusions as the company has a strong portfolio of products and is well positioned in the medical device industry. Inari Medical is also supported by long-term strategic partnerships with leading healthcare organizations. Investors should wait to see how the company performs in the future before making any decisions about their investments in Inari Medical.
Price History
On Monday, INARI MEDICAL Inc. saw its stock increase by 0.5%, with the opening price of $57.2 and closing price of $58.3. Such activity could be indicative of a shift in the direction of the company or an investment strategy by the director to realize returns on his investments. It is unclear as to what Hoffman’s motivation was for this transaction, but it is likely that investors will be watching the stock closely to see how it performs in the coming days. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Inari Medical. More…
| Total Revenues | Net Income | Net Margin |
| 469.31 | -2.77 | -0.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inari Medical. More…
| Operations | Investing | Financing |
| 34.94 | -31.55 | 1.89 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inari Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 548.84 | 96.69 | 7.88 |
Key Ratios Snapshot
Some of the financial key ratios for Inari Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 61.7% | – | 0.6% |
| FCF Margin | ROE | ROA |
| 6.3% | 0.4% | 0.3% |
Analysis
At GoodWhale, we recently conducted an analysis of INARI MEDICAL‘s financials. The star chart shows that INARI MEDICAL has an intermediate health score of 6/10, indicating that it is likely to safely ride out any crisis without the risk of bankruptcy. We classify INARI MEDICAL as a ‘gorilla’ company, meaning that it has achieved stable and high revenue or earnings growth due to its strong competitive advantage. As such, INARI MEDICAL would be well-suited for strategic investors seeking a long-term investment. After further analysis, we found that INARI MEDICAL is strong in asset, growth, and medium in profitability but weak in dividend. Investors looking for a company with strong asset and growth to support their portfolio may find INARI MEDICAL an attractive option. More…
Peers
Its competitors are OncoSil Medical Ltd, ShockWave Medical Inc, and Vycor Medical Inc.
– OncoSil Medical Ltd ($ASX:OSL)
OncoSil Medical Ltd is a medical device company that develops, manufactures and markets products for the treatment of cancer. The company has a market cap of 47.58M as of 2022 and a Return on Equity of -82.6%. OncoSil Medical’s products are designed to target and destroy cancer cells while sparing healthy tissue. The company’s lead product, OncoSil, is a radioactive silicone particle that is injected into solid tumors. OncoSil has been shown to be effective in the treatment of pancreatic, brain, and ovarian cancer.
– ShockWave Medical Inc ($NASDAQ:SWAV)
As of 2022, ShockWave Medical Inc has a market cap of 10.19B and a Return on Equity of 12.48%. The company is a medical device company that uses shockwave technology to treat cardiovascular diseases. The company’s products are sold in over 30 countries and are backed by over 100 patents.
– Vycor Medical Inc ($OTCPK:VYCO)
Vycor Medical Inc is a publicly traded company with a market capitalization of 3.1 million as of 2022. The company has a return on equity of 6.36%, which is relatively high compared to other companies in the same industry. Vycor Medical Inc is a medical device company that specializes in the development and commercialization of minimally invasive products for the neurosurgery market. The company’s products are used by surgeons to treat conditions such as brain tumors, cerebral aneurysms, and skull-base tumors.
Summary
Inari Medical Inc. recently experienced a significant insider sell alert, with Director William Hoffman selling 25,000 shares of the company. This could suggest potential trouble and investors should pay attention to this development. Analyzing the company’s overall performance may help to better understand this situation. Investors should consider this insider sell alert and perform their own due diligence before making any investment decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
